Pinkerton et al1 conclude that postexposure prophylaxis is cost-effective after moderate- to high-risk occupational exposure to human immunodeficiency virus. They analyzed a 28-day course of zidovudine, lamivudine, and indinavir, which is currently recommended by the US Public Health Service for patients with high-risk exposure.2 Baseline assumptions included wholesale drug costs but not the costs associated with adverse drug effects. However, the cost-utility ratio was sensitive to treatment cost.1
Frothingham R. Cost-effectiveness of Chemoprophylaxis After Occupational Exposure to HIV. Arch Intern Med. 1998;158(13):1469–1472. doi:
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: